Athenex Inc (ATNX) Given $25.73 Average Target Price by Brokerages

Athenex Inc (NASDAQ:ATNX) has earned an average broker rating score of 2.00 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. Athenex’s rating score has declined by 33.3% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.

Brokers have set a 12 month consensus target price of $25.73 for the company, according to Zacks. Zacks has also given Athenex an industry rank of 116 out of 265 based on the ratings given to related companies.

A number of research firms have issued reports on ATNX. JPMorgan Chase & Co. began coverage on Athenex in a research note on Wednesday, October 18th. They set a “neutral” rating and a $22.20 price target for the company. Laidlaw began coverage on Athenex in a research note on Tuesday, September 19th. They set a “buy” rating and a $36.00 price target for the company. Credit Suisse Group began coverage on Athenex in a research note on Monday, September 18th. They set an “outperform” rating and a $25.00 price target for the company. Finally, Royal Bank of Canada began coverage on Athenex in a research note on Thursday, September 14th. They set an “outperform” rating and a $35.00 price target for the company.

Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new position in shares of Athenex during the 2nd quarter valued at about $601,000. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Athenex during the 3rd quarter valued at about $1,559,000. California Public Employees Retirement System purchased a new position in shares of Athenex during the 2nd quarter valued at about $800,000. OxFORD Asset Management LLP purchased a new position in shares of Athenex during the 2nd quarter valued at about $956,000. Finally, Laurion Capital Management LP purchased a new position in shares of Athenex during the 2nd quarter valued at about $1,600,000. 2.93% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Athenex (NASDAQ ATNX) opened at $15.87 on Wednesday. The stock has a market capitalization of $920.38 and a PE ratio of -5.75. Athenex has a 52 week low of $11.21 and a 52 week high of $20.79.

COPYRIGHT VIOLATION NOTICE: “Athenex Inc (ATNX) Given $25.73 Average Target Price by Brokerages” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2018/01/03/athenex-inc-atnx-given-25-73-average-target-price-by-brokerages.html.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Get a free copy of the Zacks research report on Athenex (ATNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply